Bioventus
Guy Nohra is a co-founder of Alta Partners, and was also a partner at Burr, Egan, Deleage & Co., which he joined in 1989. Nohra has been involved in the funding and development of notable medical technology and life science companies including ATS Medical, Cutera, Innerdyne, R2 Technology, deCODE genetics, and Vesica.
Previously, Nohra was Product Manager of Medical Products with Security Pacific Trading Corporation. He was responsible for a multi-million dollar product line and traveled extensively in Korea, Taiwan, Hong Kong, China and Southeast Asia.
Currently, Nohra serves on the board of directors of several companies, including AcelRx Pharmaceuticals, Carbylan Biosurgery, PneumRx and Vertiflex, and is the Chairman of the Board of USGI Medical. He also serves on the board of directors of the Medical Device Manufacturing Association (MDMA). He was recently named to the Forbes “Midas List” of dealmakers in high-tech and life sciences. Nohra also serves as the President of the Silicon Valley chapter of The Leukemia and Lymphoma Society.
He holds a Master of Business Administration from the University of Chicago and a Bachelor of Arts in History from Stanford University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Bioventus
4 followers
Bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus accomplishes this with its orthobiologic solutions for musculoskeletal healing and regeneration that engage and enhance the body’s healing process. The company has products for bone healing, bone graft and knee osteoarthritis. Established in 2012, Bioventus is privately held and headquartered in Durham, NC. The company has more than 700 employees worldwide and its international headquarters is in Hoofddorp, The Netherlands. Bioventus also has offices in Memphis, TN and Toronto, Ontario, Canada. Bioventus works with patients, payers and health care providers throughout the world, and generates $300 million dollars in yearly revenue.